|
|
5-day change | 1st Jan Change | ||
|
4,265.00 JPY |
-1.14% | +2.16% | +2.03% | |
Published on 06/02/2025 at 02:14
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Takeda Presents Clinical Data of Polycythemia Vera Treatment at Oncology Conference |
02:14am |
MT |
|
Takeda Pharmaceutical Company Limited – Special Call |
09:05pm |
|
|
Trump’s tariffs and threatened trade actions |
May. 30 |
RE |
|
Trump’s tariffs and threatened trade actions |
May. 30 |
RE |
|
Veeva Systems Shares Rise After Q1 Results Top Expectations |
May. 29 |
MT |
|
Trump’s tariffs and threatened trade actions |
May. 28 |
RE |
|
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent |
May. 27 |
MT |
|
GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks |
May. 22 |
RE |
|
Health Rounds: Older diabetes drugs appear to slow prostate cancer in small study |
May. 21 |
RE |
|
Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 |
May. 14 |
CI |
|
Takeda Pharmaceutical Gets UK Drug Regulator’s Approval for CTTP Drug |
May. 14 |
MT |
|
UK’s MHRA Approves RADAMTS13 For Congenital Thrombotic Thrombocytopenic Purpura |
May. 12 |
RE |
|
Asian Equities Traded in the US as American Depositary Receipts Surge in Monday Trading |
May. 12 |
MT |
|
Donald Trump deals another blow to Big Pharma |
May. 12 |
 |
|
Trump’s tariffs and threatened trade actions |
May. 12 |
RE |
|
Japan’s Nikkei ends higher on US-China trade deal hopes |
May. 12 |
RE |
|
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,500 Yen, Keeps at Buy |
May. 09 |
MT |
|
Takeda Pharmaceutical to Invest $30 Billion in US Over Five Years to Strengthen R&D, Manufacturing |
May. 09 |
MT |
|
Sector Update: Health Care Stocks Decline Pre-Bell Thursday |
May. 08 |
MT |
|
Sector Update: Health Care |
May. 08 |
MT |
|
Takeda Pharmaceutical Company Limited, 2025 Earnings Call, May 08, 2025 |
May. 08 |
|
|
Takeda Pharmaceutical Fiscal Q4 Core Earnings Fall, Revenue Rises |
May. 08 |
MT |
|
Takeda’s Annual Net Profit Slumps on Expenses, Costs |
May. 08 |
DJ |
|
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 |
May. 08 |
CI |
|
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 |
May. 08 |
CI |
4502: Dynamic Chart
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company’s research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
More about the company
Buy
Last Close Price
4,314.00JPY
Average target price
5,005.59JPY
Spread / Average Target
+16.03%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
